The South Florida Water Management District's new incentive program seems to be working with nearly 100 snakes eliminated so far in 2025.

The REV102 program originated from a joint venture between Rallybio and Recursion focused on the discovery and development of novel, orally available small molecule inhibitors of ENPP1 for the ...

In addition, Rallybio may be eligible to receive certain payments in the event of Recursion’s sale of the REV102 program.

Recursion acquires full interest in Rallybio's ENPP1 inhibitor program to develop a potential oral treatment for hypophosphatasia.

In addition, Rallybio may be eligible to receive certain payments in the event of Recursion’s sale of the REV102 program.

Rallybio sells its stake in preclinical HPP drug REV102 to Recursion in a deal worth up to $25 million, including equity and milestone payments.

Under the agreement, Rallybio will also receive low single-digit royalties on future net sales and may be eligible for additional payments if Recursion sells the program.

Recursion Pharmaceuticals ( (RXRX)) just unveiled an announcement. On July 8, 2025, Recursion Pharmaceuticals acquired full ownership of the ENPP1 inhibitor program, REV102, from Rallybio, aiming ...